"Rospotrebnadzor's Vector Center received permission on July 24 to conduct clinical trials of the vaccine, the first volunteers will be vaccinated on July 27 as part of the clinical trial protocol," the statement says.
Another Russian vaccine, developed by the Gamaleya Institute of Epidemiology and Microbiology, is undergoing clinical trials at two institutions: the Burdenko Main Military Clinical Hospital and the Sechenov First Moscow State Medical University.
The vaccine is on the WHO-monitored list, along with 22 other candidate vaccines from around the world, on the path to complete all three required phases of clinical trials and get clearance for large-scale production.
The first stage of trials of the Gamaleya vaccine at Sechenov University finished last week.